Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Quercetin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE known ✓ | P06276 | 5/20 | 0.97 |
| ▸ | ACHE known ✓ | P22303 | 5/20 | 0.97 |
| ▸ | HDAC6 known ✓ | Q9UBN7 | 5/20 | 0.97 |
| ▸ | GAA known ✓ | P10253 | 4/20 | 0.97 |
| ▸ | PPARG known ✓ | P37231 | 4/20 | 0.97 |
| ▸ | MAOA known ✓ | P21397 | 4/20 | 0.97 |
| ▸ | DPP4 known ✓ | P27487 | 3/20 | 0.97 |
| ▸ | FLT3 known ✓ | P36888 | 3/20 | 0.97 |
| ▸ | CA2 known ✓ | P00918 | 3/20 | 0.97 |
| ▸ | CYP19A1 known ✓ | P11511 | 3/20 | 0.97 |
| ▸ | CDK6 known ✓ | Q00534 | 3/20 | 0.97 |
| ▸ | MAOB known ✓ | P27338 | 2/20 | 0.97 |
| ▸ | MMP1 known ✓ | P03956 | 2/20 | 0.97 |
| ▸ | EGFR known ✓ | P00533 | 1/20 | 0.97 |
| ▸ | LCK known ✓ | P06239 | 1/20 | 0.97 |
| ▸ | RET known ✓ | P07949 | 1/20 | 0.97 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.97 |
| ▸ | MET known ✓ | P08581 | 1/20 | 0.97 |
| ▸ | CDK4 known ✓ | P11802 | 1/20 | 0.97 |
| ▸ | SRC known ✓ | P12931 | 1/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Quercetin SCHEMBL31168046 | 1.00 | MEN1 (0.97) | MEN1KMT2ACYP1A2CYP3A4KDM4E | |
| Quercetin SCHEMBL29353785 | 0.99 | MEN1 (1.00) | MEN1KMT2ACYP1A2CYP3A4KDM4E | |
| Quercetin SCHEMBL31507620 | 0.99 | MEN1 (1.00) | MEN1KMT2ACYP1A2CYP3A4KDM4E | |
| Quercetin SCHEMBL118425 | 0.99 | MEN1 (1.00) | MEN1KMT2ACYP1A2CYP3A4KDM4E | |
| Quercetin SCHEMBL19723 | 0.99 | MEN1 (1.00) | MEN1KMT2ACYP1A2CYP3A4KDM4E | |
| Quercetin SCHEMBL29351036 | 0.99 | MEN1 (1.00) | MEN1KMT2ACYP1A2CYP3A4KDM4E | |
| Quercetin SCHEMBL29723041 | 0.99 | MEN1 (1.00) | MEN1KMT2ACYP1A2CYP3A4KDM4E | |
| Quercetin SCHEMBL17629824 | 0.99 | MEN1 (1.00) | MEN1KMT2ACYP1A2CYP3A4KDM4E | |
| Quercetin SCHEMBL28763574 | 0.97 | MEN1 (0.95) | MEN1KMT2ACYP1A2CYP3A4KDM4E | |
| Quercetin SCHEMBL3786991 | 0.97 | MEN1 (0.97) | MEN1KMT2ACYP1A2CYP3A4KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113768920-A | Application of quercetin and/or medicinal derivatives thereof in preparation of anti-enterovirus medicines | 武汉市金银潭医院(武汉市传染病医院) | 2021-12-10 | — | — | CN | claimed |
| CN-105963247-A | Preparation method of injection medicine for improving stability of quercetin medicine injection preparation | 成都易创思生物科技有限公司 | 2016-09-28 | — | — | CN | disclosed |
| US-20040162247-A1 | Therapeutic agent or osteoporosis comprising an active ingredient of quercetin derivatives | KIM CHUNG-SOOK (KR) | 2004-08-19 | — | — | US | disclosed |
| EP-1309326-A1 | A THERAPEUTIC AGENT OF OSTEOPOROSIS COMPRISING AN ACTIVE INGREDIENT OF QUERCETIN DERIVATIVES | Korea Institute of Oriental Medicine (KR) | 2003-05-14 | — | — | EP | disclosed |
| US-20020165169-A1 | Therapeutic agent of osteoporosis comprising an active ingredient of quercetin derivatives | KOREA INSTITUTE OF ORIENTAL MEDICINE (KR) | 2002-11-07 | — | — | US | disclosed |
| WO-2002017909-A1 | A THERAPEUTIC AGENT OF OSTEOPOROSIS COMPRISING AN ACTIVE INGREDIENT OF QUERCETIN DERIVATIVES | KOREA INSTITUTE OF ORIENTAL MEDICINE (KR) | 2002-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040162247-A1 | Therapeutic agent or osteoporosis comprising an active ingredient of quercetin derivatives | NFATC1, MKI67, SOST | BCHE 1642/4885ACHE 58/4885HDAC6 1559/4885 |
| US-20020165169-A1 | Therapeutic agent of osteoporosis comprising an active ingredient of quercetin derivatives | NFATC1, MKI67, SOST | BCHE 1608/4885ACHE 58/4885HDAC6 1525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.